Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/11/2793833/0/en/Pasithea-Therapeutics-Announces-Positive-In-Vivo-Preclinical-Efficacy-Data-for-PAS-004-from-NRAS-Mutation-Cancer-Xenograft-Models.html

— Preclinical data continues to demonstrate PAS-004’s potentially superior properties as compared to FDA approved MEK inhibitors —

— Once daily dose of PAS-004 delivers anti-tumor efficacy in in vivo NRAS mutation cancer models —

Read more at globenewswire.com

Related news for (KTTA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.